Julian Harrison
Stock Analyst at BTIG
(4.70)
# 227
Out of 5,182 analysts
119
Total ratings
59.82%
Success rate
32.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Maintains: Buy | $78 → $151 | $75.00 | +101.33% | 7 | Apr 27, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $151 → $178 | $84.48 | +110.70% | 5 | Apr 20, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Buy | $70 → $98 | $69.88 | +40.24% | 8 | Apr 13, 2026 | |
| AVTX Avalo Therapeutics | Reiterates: Buy | $40 | $14.29 | +179.92% | 4 | Apr 13, 2026 | |
| CLYM Climb Bio | Reiterates: Buy | $8 | $9.55 | -16.23% | 4 | Apr 8, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $4 | $1.42 | +182.69% | 5 | Apr 7, 2026 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $10 | $2.41 | +314.94% | 4 | Apr 1, 2026 | |
| TVRD Tvardi Therapeutics | Reiterates: Buy | $15 | $3.19 | +370.22% | 2 | Apr 1, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Buy | $30 | $16.85 | +78.04% | 6 | Mar 30, 2026 | |
| MAZE Maze Therapeutics | Reiterates: Buy | $46 | $25.49 | +80.46% | 6 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $137 | $86.08 | +59.16% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $16.64 | +26.20% | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $39 | $26.89 | +45.04% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $50 | $36.72 | +36.17% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $23.64 | +48.05% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $111.56 | +34.46% | 5 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $6.03 | +182.16% | 3 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $1 | $0.28 | +263.50% | 3 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.12 | +60.26% | 5 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $38 | $12.90 | +194.57% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $6.94 | +534.00% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $13.40 | +355.22% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $98.28 | -16.56% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.38 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $66.04 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.27 | +3,214.92% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $4.32 | +85.40% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.64 | +1,158.85% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.61 | +24,635.21% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $566.71 | - | 2 | Feb 11, 2022 |
Oruka Therapeutics
Apr 27, 2026
Maintains: Buy
Price Target: $78 → $151
Current: $75.00
Upside: +101.33%
Nektar Therapeutics
Apr 20, 2026
Maintains: Buy
Price Target: $151 → $178
Current: $84.48
Upside: +110.70%
Spyre Therapeutics
Apr 13, 2026
Maintains: Buy
Price Target: $70 → $98
Current: $69.88
Upside: +40.24%
Avalo Therapeutics
Apr 13, 2026
Reiterates: Buy
Price Target: $40
Current: $14.29
Upside: +179.92%
Climb Bio
Apr 8, 2026
Reiterates: Buy
Price Target: $8
Current: $9.55
Upside: -16.23%
Akebia Therapeutics
Apr 7, 2026
Reiterates: Buy
Price Target: $4
Current: $1.42
Upside: +182.69%
Connect Biopharma Holdings
Apr 1, 2026
Reiterates: Buy
Price Target: $10
Current: $2.41
Upside: +314.94%
Tvardi Therapeutics
Apr 1, 2026
Reiterates: Buy
Price Target: $15
Current: $3.19
Upside: +370.22%
MoonLake Immunotherapeutics
Mar 30, 2026
Reiterates: Buy
Price Target: $30
Current: $16.85
Upside: +78.04%
Maze Therapeutics
Mar 25, 2026
Reiterates: Buy
Price Target: $46
Current: $25.49
Upside: +80.46%
Mar 23, 2026
Reiterates: Buy
Price Target: $137
Current: $86.08
Upside: +59.16%
Mar 20, 2026
Reiterates: Buy
Price Target: $21
Current: $16.64
Upside: +26.20%
Mar 16, 2026
Maintains: Buy
Price Target: $28 → $39
Current: $26.89
Upside: +45.04%
Mar 5, 2026
Maintains: Buy
Price Target: $49 → $50
Current: $36.72
Upside: +36.17%
Feb 26, 2026
Reiterates: Buy
Price Target: $35
Current: $23.64
Upside: +48.05%
Feb 25, 2026
Reiterates: Buy
Price Target: $150
Current: $111.56
Upside: +34.46%
Feb 20, 2026
Reiterates: Buy
Price Target: $17
Current: $6.03
Upside: +182.16%
Jan 16, 2026
Reiterates: Buy
Price Target: $1
Current: $0.28
Upside: +263.50%
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $3.12
Upside: +60.26%
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $12.90
Upside: +194.57%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.94
Upside: +534.00%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $13.40
Upside: +355.22%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $98.28
Upside: -16.56%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $11.38
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $66.04
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.27
Upside: +3,214.92%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $4.32
Upside: +85.40%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.64
Upside: +1,158.85%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.61
Upside: +24,635.21%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $566.71
Upside: -